180 Life Sciences Past Earnings Performance

Past criteria checks 0/6

180 Life Sciences's earnings have been declining at an average annual rate of -14.3%, while the Biotechs industry saw earnings growing at 14.7% annually.

Key information

-14.3%

Earnings growth rate

21.0%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	n/a
Net Margin	n/a
Last Earnings Update	31 Dec 2023

Recent past performance updates

No updates

Recent updates

180 Life Sciences to raise $6.5M in direct stock offering

Jul 18

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

Sep 08

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

Feb 17

SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today

Nov 27

Revenue & Expenses Breakdown
Beta

How 180 Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:ATNF Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	-20	11	3
30 Sep 23	-40	14	3
30 Jun 23	-52	15	3
31 Mar 23	-45	16	3
31 Dec 22	-39	15	2
30 Sep 22	-16	13	4
30 Jun 22	24	13	4
31 Mar 22	-3	12	4
31 Dec 21	-20	12	4
30 Sep 21	-30	11	3
30 Jun 21	-50	7	3
31 Mar 21	-26	5	2
31 Dec 20	-12	3	2
30 Sep 20	-29	20	3
30 Jun 20	-28	20	3
31 Mar 20	-28	20	3
31 Dec 19	-25	19	2
30 Sep 19	-4	3	1
30 Jun 19	-6	4	1

Quality Earnings: ATNF is currently unprofitable.

Growing Profit Margin: ATNF is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ATNF is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.

Accelerating Growth: Unable to compare ATNF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATNF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).

Return on Equity

High ROE: ATNF's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

180 Life Sciences Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

180 Life Sciences Corp. Announces Chief Executive Officer Changes

180 Life Sciences Corp. Announces Board Resignations

180 Life Sciences Corp. Announces Resignation of Donald A. Mcgovern, as Member of the Board of Directors

Nasdaq Provides 180 Life Sciences Written Notice That It Complies with Terms of Prior Extension, Company Complies with Listing Rule 5635(d)(1)(A)

180 Life Sciences Receives a Letter from Nasdaq

High number of new directors

180 Life Sciences Corp. Receives Formal Written Scientific Response from the United Kingdom's Medicines and Healthcare Products Regulatory Agency

180 Life Sciences Receives Non-Compliance Notice From Nasdaq

180 Life Sciences Corp. Receives Non-Compliance Letter from Nasdaq

New minor risk - Share price stability

180 Life Sciences Announces an Agreement for A Clinical Pharmacology Study Testing A New Formulation of Cbd for Enhanced Oral Uptake

180 Life Sciences Corp. Provides Update on Regulatory Approval Process in the UK and US for Dupuytren's Disease Treatment

180 Life Sciences Corp., Annual General Meeting, Jul 06, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

180 Life Sciences Provides Update on Progress to Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

No longer forecast to breakeven

Price target decreased to US$4.00

High number of new and inexperienced directors

180 Life Sciences Receives Non-Compliance Letter from Nasdaq

180 Life Sciences Corp. Announces the First Patient Has Been Randomized in the Clinical Trial to Evaluate Anti-Tumor Necrosis Factor (TNF) for Patients with Early-Stage, Pain Predominant Frozen Shoulder

180 Life Sciences Corp. has completed a Follow-on Equity Offering in the amount of $6.500001 million.

180 Life Sciences to raise $6.5M in direct stock offering

180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease

180 Life Sciences Corp. Announces Following Publication of Promising Data from A Phase 2B Dupuytren’S Trial

180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology

Price target decreased to US$5.00

High number of new and inexperienced directors

180 Life Sciences Corp., Annual General Meeting, Jun 14, 2022

180 Life Sciences Corp. Provides an Update on its Anticipated Preliminary Discussion

180 Life Sciences Corp. Forms Scientific Advisory Board

Lead Independent Director recently bought US$103k worth of stock

180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results

180 Life Sciences: Looking At Inflammation With Cannabis (Podcast)

180 Life Sciences Corp. announced that it has received $15 million in funding

180 Life Sciences Corp. announced that it expects to receive $15 million in funding

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)

180 Life Sciences Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

180 Life Sciences Corp. announced delayed 10-Q filing

180 Life Sciences Corp. announced delayed annual 10-K filing

180 Life Sciences Receives Extension Until June 30, 2021 to Regain Compliance from Nasdaq

180 Life Sciences Corp. announced that it expects to receive $11.6662 million in funding

What Type Of Shareholders Make Up 180 Life Sciences Corp.'s (NASDAQ:ATNF) Share Registry?

New 90-day high: US$6.72

180 Life Sciences Corp. Announces Management Changes

180 Life Sciences Corp. Appoints Ozan Pamir to Serve as the Interim Chief Financial Officer

SPAC biotech 180 Life Sciences to ring Nasdaq opening bell today

180 Life Sciences Corp. announced delayed 10-Q filing

180 Life Sciences Corp. Announces Management Changes

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta